First-line PD-1/PD-L1 inhibitor combination regimens — the pembrolizumab plus platinum-5-FU chemotherapy and emerging nivolumab-based combinations replacing platinum-doublet chemotherapy as the standard first-line treatment for recurrent or metastatic squamous cell carcinoma of the head and neck — create the highest-value treatment segment, with the Head and Neck Cancer Market...
จองคิวบริการ
NR tours
Youplay
NR shop
NR jobs
facebook th
Spanish 
thai
English
French
Portuguese
Italiano
Romaian
Portuguese (Brazil)
china